5 Healthcare Stocks Insiders Are Buying

Page 1 of 5

In this article, we will list the 5 Healthcare Stocks Insiders Are Buying. Please visit 8 Healthcare Stocks Insiders Are Buying if you would like to see the extended list and the methodology behind it.

15 Healthiest Countries In Africa

5. Aktis Oncology, Inc. (NASDAQ:AKTS)

On March 31, 2026, H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology, Inc. (NASDAQ:AKTS) to $33 from $30 previously and maintained a Buy rating on the shares. Robert Burns has said that the company’s pipeline is expected to advance and expand over the next twelve months.

On March 30, 2026, Aktis Oncology, Inc. (NASDAQ:AKTS) announced the FDA clearance of investigational new drug applications to begin a Phase 1b trial for AKY-25191, a miniprotein radioconjugate targeting B7-H3 across multiple solid tumors, including prostate and lung cancers.

Aktis Oncology, Inc. (NASDAQ:AKTS) said that AKY-2519 is its second clinical-stage miniprotein radioconjugate, while its lead program, AKY-1189, targeting Nectin-4, is already enrolling in a Phase 1b study, with both designed to deliver actinium-225 to tumor sites.

Aktis Oncology, Inc. (NASDAQ:AKTS) develops radiopharmaceutical therapies for solid tumors.

Page 1 of 5